Cargando...
Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...
Guardado en:
| Publicado en: | J Clin Med |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/ https://ncbi.nlm.nih.gov/pubmed/30889854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|